Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Ciobanu

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
American Journal of Obstetrics and Gynecology|February 1, 1989
CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantationN Ciobanu, C D Runowicz, P H Wiernik, et al.
American Journal of Clinical Oncology|February 1, 1988
Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinomaS Wadler, A I Einzig, J P Dutcher, et al.
Transfusion|March 1, 1992
Experience with autologous bone marrow harvesting and transfusion of marrow-derived red cellsN Ciobanu, V Weinberg, J A Sparano, et al.
Annals of Internal Medicine|January 15, 1994
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG)J M Rowe, N Ciobanu, J Ascensao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1983
Immunologic effects of interleukin 2 in primary immunodeficiency diseasesN Flomenberg, K Welte, R Mertelsmann, et al.
International Journal of Antimicrobial Agents|July 1, 1996
Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patientsH M Lazarus, R J Creger, R Gucalp, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2E T Walpole, J P Dutcher, J Sparano, et al.
Cancer Research|August 1, 1987
Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cellsS L Marcus, J P Dutcher, E Paietta, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 27, 2022
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in MoldovaL Cates, A Codreanu, N Ciobanu, et al.
Journal of Clinical Immunology|July 1, 1984
Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiencyG Kruger, K Welte, N Ciobanu, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
American Journal of Obstetrics and Gynecology|February 1, 1989
CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantationN Ciobanu, C D Runowicz, P H Wiernik, et al.
American Journal of Clinical Oncology|February 1, 1988
Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinomaS Wadler, A I Einzig, J P Dutcher, et al.
Transfusion|March 1, 1992
Experience with autologous bone marrow harvesting and transfusion of marrow-derived red cellsN Ciobanu, V Weinberg, J A Sparano, et al.
Annals of Internal Medicine|January 15, 1994
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG)J M Rowe, N Ciobanu, J Ascensao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1983
Immunologic effects of interleukin 2 in primary immunodeficiency diseasesN Flomenberg, K Welte, R Mertelsmann, et al.
International Journal of Antimicrobial Agents|July 1, 1996
Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patientsH M Lazarus, R J Creger, R Gucalp, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2E T Walpole, J P Dutcher, J Sparano, et al.
Cancer Research|August 1, 1987
Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cellsS L Marcus, J P Dutcher, E Paietta, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 27, 2022
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in MoldovaL Cates, A Codreanu, N Ciobanu, et al.
Journal of Clinical Immunology|July 1, 1984
Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiencyG Kruger, K Welte, N Ciobanu, et al.
Pageof 3